Quantcast

Latest Exenatide Stories

2014-07-17 04:21:04

MT Services LLC informs plaintiffs on various pharmaceutical drug cases available to obtain lawsuit funding and legal assistance BRONX, N.Y., July 17, 2014 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company, which operates lawsuitsettlementnews.com announced today a primary focus on assisting plaintiffs of bad pharmaceutical drugs such as AndgroGel: Testosterone Creams, Accutane, Acetaminophen, Actos, Avandia, Byetta-Januvia-Victoza, Birth Control Products:...

2014-07-05 23:01:25

The Firm is evaluating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis or thyroid cancer, due to their use of the Type 2 diabetes medication. New York, NY (PRWEB) July 05, 2014 Hundreds of Byetta lawsuits (http://www.byettalawsuit.com) and other incretin mimetic claims continue to move forward in a federal multidistrict litigation underway in U.S. District Court, Southern District of California, Bernstein Liebhard LLP reports. According to...

2014-06-27 04:21:25

Pre-Settlement Case Funding Firm announces new program focus for plaintiffs of Byetta, as well as Actos, Januvia, and Victoza cases. LOS ANGELES, June 27, 2014 /PRNewswire/ -- Legal-Bay LLC, the Lawsuit Settlement Funding Company, disclosed today a new lawsuit cash advance program that helps clients with cases facing Byetta complications. In 2011, after California medical researchers discovered that patients using Byetta are 3 times more at risk for Pancreatic cancer, the number of...

2014-06-19 04:21:32

Pre-Settlement Case Funding Firm announces new program focus for plaintiffs who used Actos, as well as Byetta, Januvia, and Victoza NEW ORLEANS, June 19, 2014 /PRNewswire/ -- Legal-Bay LLC, the Lawsuit Settlement Funding Company, disclosed today a new-implemented program involving lawsuit cash advances for clients facing complications due to risky Actos prescription drugs. In April 2014, Terrence and Susan Allen were awarded $9 billion from the Louisiana jury in the first official...

2014-06-15 08:21:29

-- The average HbA1C reductions in patients treated with ITCA 650 for 6 months at the time of the interim analysis were -3.2%; patients at baseline had HbA1C levels between 10-12%. BOSTON, June 15, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the highlights of a poster presentation at the 74(th) Scientific Sessions of the American Diabetes Association (ADA) held in San Francisco that contained the first 6-month data from an ongoing open-label phase 3 trial...

2014-05-17 23:01:16

The Firm is investigating Byetta lawsuits on behalf of individuals who allegedly developed pancreatic cancer, pancreatitis and thyroid cancer due to their use of the Type 2 diabetes medication. New York, New York (PRWEB) May 17, 2014 Byetta lawsuits (http://www.byettalawsuit.com) and other product liability claims involving a class of diabetes drugs called incretin mimetics continue to mount in a federal multidistrict litigation now underway in U.S. District Court, Southern District of...

2014-05-15 08:31:10

TORONTO, May 15, 2014 /PRNewswire/ - Transition Therapeutics Inc. ("Transition" or the "Company") (NASDAQ: TTHI, TSX: TTH) today announced the dosing of the first patient in a Phase 2 clinical study of TT-401 (LY2944876), a drug candidate for the treatment of type 2 diabetes. The study is expected to enroll up to 375 type 2 diabetes subjects and will be performed by Transition's development partner, Eli Lilly and Company ("Lilly"). The objectives of the study will be to...

2014-05-07 09:50:08

Follow-up study published in the Journal of Parkinson's Disease supports an earlier 'proof of concept' trial A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier "proof of concept" clinical trial using exenatide showed that improvements persisted twelve months after discontinuing exenatide therapy. These data provide strong encouragement for the further study of this drug in patients with PD, report researchers in the Journal of Parkinson's Disease....

2014-04-17 23:01:33

The Firm is actively evaluating Byetta lawsuit claims on behalf of diabetics who allegedly developed pancreatitis, pancreatic cancer or thyroid cancer after taking the incretin mimetic. New York, NY (PRWEB) April 17, 2014 More than 30 federal cases have joined a federal diabetes drug litigation that includes an increasing number of Byetta lawsuit (http://www.byettalawsuit.com/) filings, as well as claims over similarly-designed medications, Bernstein Liebhard LLP reports. Court documents...

2014-04-01 08:28:59

-Promising first interim phase 3 data for ITCA 650 in type 2 diabetes, combined with robust execution against key milestones and the addition of key talent BOSTON, April 1, 2014 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the completion of another landmark private round of equity financing for $200 million. Together with the $210 million round of equity and debt financing in November of 2012 the company is very strongly positioned for future milestones and launch...


Latest Exenatide Reference Libraries

36_67c6fec75293d7e1e91a0c52aa692cf7
2005-06-22 14:17:05

The Gila monster (Heloderma suspectum) is one of the two known species of venomous lizards. This lizard lives in the deserts of the southwestern USA and northwestern Mexico. It is a heavy, slow moving lizard and can measure up to 2 feet (60 cm) in length. Its skin has the appearance of beads in the colors black, pink, orange, and yellow, laid down in intricate patterns across the animal's body. Unlike a snake, the Gila monster envenomates its victim through grooves in the teeth of its...

More Articles (1 articles) »
Word of the Day
bibliopole
  • A bookseller; now, especially, a dealer in rare and curious books.
This word comes from a Greek phrase meaning 'book seller.'
Related